logo
84% of world's coral reefs struck by worst bleaching event in history

84% of world's coral reefs struck by worst bleaching event in history

Yahoo23-04-2025

April 23 (UPI) -- More than 80% of the world's coral reefs fell victim to harmful bleaching and is now in "uncharted territory" with the worst global bleaching event in recorded history.
The coral reef system in at least 82 nations and other territories have been exposed to enough heart to turn at least 84% of the world's coral white since the global event started last year in January, according to data by the U.S. government's Coral Reef Watch.
"Reefs have not encountered this before," said Dr. Britta Schaffelke of the Australian Institute of Marine Science and coordinator of the Global Coral Reef Monitoring Network, adding it was "unprecedented" and now the most intense event of its kind ever recorded.
When water is too warm, coral will expel the algae -- otherwise known as zooxanthellae -- living in their tissues which causes the coral to turn completely white, according to the National Oceanic and Atmospheric Administration.
During coral bleaching events, environmental stress like temperature change will trigger a breakup of the symbiotic relationship between coral and algae, which is now spreading like a wildfire to corals across the Pacific, Atlantic and Indian oceans and killing countless coral habitats.
Otherwise known as the "rainforests of the sea," coral supports biodiversity and about a third of all marine species and at least a billion people.
Although corals can recover from bleaching if temperatures are less extreme, past surveys have indicated a bleak picture of widespread global coral elimination.
NOAA said last April that the world's oceans were undergoing the fourth global coral bleaching event on record and its second in the last 10 years as scientists in Florida, Mexico and the Caribbean raised alarm bells that summer over extreme bleaching in the northern hemisphere.
Scientists further describe a "graveyard of dead corals" in Australia's northern Great Barrier Reef following 2024's bleaching event that caused about 40% of its coral life to die in one spot to its south.
In Florida, where divers worked to save the Sunshine State's coral reefs, an average of one in five corals were lost and on Mexico's Pacific side, one area lost nearly 93% of its corals. But while warming water temps -- a result of climate change -- are a primary driver, newer research suggests that nitrogen pollution is the main cause of coral bleaching in Florida.
Meanwhile, almost a quarter of corals were killed by heat last year in the middle of the Indian Ocean in the remote Chagos Islands.
"Bleaching is always eerie -- as if a silent snowfall has descended on the reef," said Melanie McField, founder of the Caribbean-based Healthy Reefs for Health People initiative. "There is usually an absence of fluttering fish and an absence of the vibrant colors on the reef. It's an ashen pallor and stillness in what should be a rowdy vibrant reefscape."
The report came as U.S. President Donald Trump has taken steps to boost fossil fuel production and a rollback of clean energy programs.
"World leaders need to really commit to reduce fossil fuels and increase investments in clean energies and make it a reality," said Dr. Valeria Pizarro, a senior coral scientist at the Perry Institute for Marine Science working on reefs in the Bahamas and Caribbean Sea.
The small island nation of Palau in the western Pacific experienced intense marine heatwaves in 1998, 2010 and 2017, but interestingly, each successive event led to less coral bleaching. However, scientific consensus is that ultimately the future of coral reefs will depend on a rapid reduction of carbon emissions which runs counter to Trump administration policy.
"We need them to stop having it on paper and on the news, we need it to be real," Pizarro said.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Tagomics awarded £860k grant for colorectal cancer diagnostic
Tagomics awarded £860k grant for colorectal cancer diagnostic

Yahoo

time2 hours ago

  • Yahoo

Tagomics awarded £860k grant for colorectal cancer diagnostic

Tagomics has been awarded £860,000 ($1.1m) from Innovate UK to develop a test for diagnosing early-stage colorectal cancer (CRC). The Cambridge, UK-based company said the money from the UK government innovation agency's Biomedical Catalyst programme would help fund a £1.2m project that is applying its Interlace multiomics workflow platform towards the detection of genetic and epigenetic mutations associated with CRC. This includes the development of new models for analysing patients' multiomic profiles to identify new disease biomarkers. Once the project concludes, a pilot study of the diagnostic test will be undertaken with the UK National Health Service (NHS). Led by Dr Arash Assadsangabi, consultant physician and gastroenterologist at Salford Royal NHS Foundation Trust, in collaboration with the Northern Care Alliance Research Collection biobank, the study will profile 250 patients suspected of having CRC to validate identified biomarkers and demonstrate multiomic profiling's efficacy in the early detection of the disease. Tagomics' chief scientific officer and co-founder, Dr Robert Neely said: 'We believe that the unique, information-rich dataset that Interlace provides us will be pivotal in detecting CRC at the earliest possible stages of development, enabling treatment of the cancer when it is most vulnerable to modern therapeutics, with the aim of dramatically improving patient outcomes.' Upon completion of the project, Tagomics will look to further expand the capabilities and applications of its Interlace platform with the support of Agilent Technologies, building on an established partnership that was key to the early development of the platform, Dr Neely added. The American Cancer Society estimates that there will be 107,320 new cases of colon cancer and 46,950 new cases of rectal cancer in 2025. According to GlobalData analysis, with early detection of CRC critical in reducing the disease's mortality rate, in vitro diagnostic (IVD) tests have a critical role to play in bridging the disease's screening gap, with company's such as Guardant Health at work on developing patient-first tests to create solutions that make patient care more accessible. Guardant's SHIELD test, which was approved by the US Food and Drug Administration (FDA) as a primary screening option for CRC in 2024, is intended to detect alterations in the blood associated with CRC. "Tagomics awarded £860k grant for colorectal cancer diagnostic" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Toxic 'forever chemical' showing up in European food and wine
Toxic 'forever chemical' showing up in European food and wine

Yahoo

time4 hours ago

  • Yahoo

Toxic 'forever chemical' showing up in European food and wine

A team of researchers has found "alarmingly high" levels of trifluoroacetic acid (TFA), a so-called forever chemical, in dozens of organic and non-organic pastas, baked goods and breakfast cereals from Europe, as well as in wine. "In conventional grain products, the average levels were so high that a health risk to children can no longer be ruled out," said Helmut Burtscher-Schaden, an environmental chemist part of the Brussels-based Pesticide Action Network (PAN) Europe, which describes TFA as a "product of PFAS pesticides and industrial chemicals." Forever chemicals, also known as PFAS, are thousands of long-lasting substances used in household and everyday products since the middle of the 20th century but which have been found to be difficult to remove from the environment and from human bodies. The latest research points to 'widespread contamination from PFAS (per- and poly-fluoroalkyl substances) pesticides," PAN Europe said, warning that TFA tends to build up in water and farmland. The amount of TFA in the food items was found to be three times that recorded in a similar study eight years ago, according to PAN Europe, which in April warned of "dramatic rise" of TFA in wine. In a report covering wines from Austria, Belgium, Croatia, France, Germany, Greece, Hungary, Italy, Luxembourg and Spain, PAN Europe found that while pre-1988 vintages do not contain any such contamination, there has been a "sharp increase" in pesticide and chemical residues in wine bottled since 2010. Such a "steep accumulation" should be "a red flag that calls for decisive action," according to Michael Müller, a professor of pharmaceutical and medicinal chemistry at the University of Freiburg. The European Chemicals Agency has warned that TFA "may cause harm to the unborn child" and "may impair fertility."

NeuroSigma Announces Notice of Allowance for Patent Protecting Monarch eTNS System in China
NeuroSigma Announces Notice of Allowance for Patent Protecting Monarch eTNS System in China

Yahoo

time4 hours ago

  • Yahoo

NeuroSigma Announces Notice of Allowance for Patent Protecting Monarch eTNS System in China

LOS ANGELES, June 10, 2025 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Los Angeles-based bioelectronics company commercializing the Monarch external Trigeminal Nerve Stimulation (eTNS) device for treating attention-deficit hyperactivity disorder (ADHD), today announced a notice of allowance in China for a patent protecting the Monarch eTNS System. The patent, titled Pulse Generator for Trigeminal Nerve Stimulation, protects certain embodiments of NeuroSigma's core eTNS technology, including its second-generation Monarch device. The patent was allowed by China's National Intellectual Property Administration on May 27, 2025. In 2022, NeuroSigma licensed rights to the Monarch eTNS System for treating ADHD in China to Ignis Therapeutics, a leader in the development of novel therapeutics for central nervous system (CNS) conditions. 'As NeuroSigma continues to grow and work with our partners at Ignis, China will be a critical market for the Monarch eTNS System,' said Colin Kealey, M.D., President and CEO of NeuroSigma. 'This patent protects our second-generation Monarch device in China and significantly strengthens the company's intellectual property position.' "NeuroSigma's Monarch eTNS System is a highly innovative and effective therapy for ADHD,' added Tom Paschall, Director of NeuroSigma and CEO of Checkmate Capital. 'China is one of the largest and most important markets in the world for new CNS therapies. With this patent award, the Monarch device will benefit from robust intellectual property protection, which, we believe, will facilitate commercialization in this key market.' About NeuroSigma NeuroSigma is a Los Angeles, California-based bioelectronic medical device company developing technologies to transform medical practice and patients' lives. The company's lead product is the Monarch eTNS System, which is the first non-drug treatment for pediatric ADHD cleared by the FDA. Pipeline indications for the Monarch eTNS System include neurodevelopmental disorders such as autism spectrum disorder (ASD), learning disabilities, and epilepsy. NeuroSigma has received Breakthrough Device Designation for the Monarch eTNS System from the FDA in drug-resistant epilepsy. For more information about NeuroSigma, please visit For more information on the Monarch eTNS System, please visit Contact:Colin Kealey, M.D., President of NeuroSigma at CKealey@

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store